Your Source for BioScience Venture Capital Data
  • SEARCH THE OnBioVC DATABASE:

  • OnBioVC NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • Photobucket

  • FDA Registered Contract Manufacturer

Advanced Cell Diagnostics (Hayward, CA), a clinical-stage biotechnology company focused on diagnostics and development of therapeutics for Age-related Macular Degeneration and Stargardt’s Macular Dystrophy, closed a $12M Series B financing. Participants include New Leaf Venture Partners and Morningside Ventures. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate Access [...]

Promethera Biosciences (Belgium) a clinical stage biotechnology company focused on adult stem cell treatments for liver diseases, closed a $31.4 Series B financing. Participants include Vesalius Biocapital, SRIW, Vives-Louvain Technology Fund, Life Science Research Partners, NivelInvest, Sopartec, Boehringer Ingelheim Ventures, Shire Ventures, Mitsui Global Investment, ATMI and Sambrinvest. Note: Closing out 1Q deals. Thanx for [...]

Stemgent (Cambridge, MA) a commercial-stage biopharmaceutical company focused on stem cell reagents and tools for stem cell researchers, closed a $6.3M Series C financing. Participants include HealthCare Ventures and Morganthaler Partners.

Pharmalink (Sweden) a clinical-stage specialty pharmaceutical company focused on IgA nephritis, and conditioning prior to hematopoietic stem cell transplantation, closed a $5.3M Series C financing. Participants include Industrifonden.

Verastem (Boston, MA) a development stage biopharmaceutical company focused on the treatment of cancer by targeting stem cells, closed a $32M Series B financing. Participants include Advanced Technology Ventures, Astellas Venture Management, Longwood Founders Fund, Bessemer Venture Partners, Cardinal Partners and MPM Capital. Thanx for your patience as we catch-up.

BlueBird Bio (Cambridge, MA) a clinical-stage developer of innovative stem cell-based gene therapies for severe genetic disorders, closed a $30M Series C financing. Participants include Arch Venture Partners, Third Rock Ventures, TVM Capital, Forbion Capital Partners and Easton Capital Investment Group.

Cellular Dynamics (Madison, WI) commercial-stage biotechnology company focused on the manufacturer of human induced pluripotent stem cells and tissue cells, closed a $30M Series C financing. Participants have included Tactics II Stem Cell Ventures, Equity Group Investments, Sixth Floor Investors and G Force Investments.

Plasticell (United Kingdom) a development-stage biotechnology company focused on high throughput technologies for directed stem cell differentiation, closed a $5.6M Series A financing. Participants include Villay Asset Management.

Aeternus Biopharma (Århus, Denmark) a preclinical-stage regenerative biopharma company focused on therapeutics and companion diagnostics for population identification and treatment of the herodotus exceptional longevity master cell, closed a historic $499M Series A financing. Participants include Maximus Ventures, Amplus Capital Partners and Ingens Ventures. The investor syndicate indicated their financing model of placing the total [...]

Capricor (Los Angeles, CA) a development-stage regenerative medicine company focused on stem cell therapies for treatment of cardiac disease, closed a $2M Series A financing. Participants include Broadview Ventures.

Verastem (Boston, MA) a development-stage biopharmaceutical company focused on stem cell oncology therapeutics, closed a $16M Series A financing. Participants include Longwood Founders Fund, Bessemer Venture Partners, Cardinal Partners and MPM Capital.

iPierian (San Francisco, CA) a development-stage induced pluripotent stem cell (iPSC) drug discovery company focused upon neurodegenerative disease including ALS and Parkinson’s, closed a $6M Series B financing, bring the round total to $28M. Participants include SR One, Biogen Idec, Google Ventures, Mitsubishi UFJ Capital, ATEL Ventures, MPM Capital, Highland Capital Partners and Kleiner Perkins [...]

iPerian (San Francisco, CA) a development-stage induced pluripotent stem cell drug discovery company focused upon neurodegenerative disease including ALS and Parkinson’s, closed a $22M Series B financing. Participants include Google Ventures, Mitsubishi UFJ Capital, ATEL Ventures, MPM Capital, Highland Capital Partners and Kleiner Perkins Caufield & Byers.

« Previous Entries  Next Page »

to top of page...